REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
636.34 USD   -1.91%
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Jefferies Starts Regeneron Pharmaceuticals at Underperform With $536 Price Target

06/06/2022 | 05:35am EDT


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main..
MT
08/04Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta..
MT
08/04Regeneron Pharmaceuticals - NOVEL COSTIMULATORY BISPECIFIC ANTIBODY SHOWS ENCOURAGING A..
AQ
08/04RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto..
MT
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2..
DJ
08/03US STOCKS-Strong earnings lift Wall Street ahead of services activity data
RE
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 798 M - -
Net income 2022 3 807 M - -
Net cash 2022 4 839 M - -
P/E ratio 2022 18,5x
Yield 2022 -
Capitalization 68 030 M 68 030 M -
EV / Sales 2022 5,36x
EV / Sales 2023 4,44x
Nbr of Employees 10 715
Free-Float 80,5%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 636,34 $
Average target price 676,32 $
Spread / Average Target 6,28%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.0.76%68 030
GILEAD SCIENCES, INC.-9.08%82 747
VERTEX PHARMACEUTICALS37.98%76 740
WUXI APPTEC CO., LTD.-22.47%39 407
BIONTECH SE-41.02%36 949
GENMAB A/S0.99%23 720